OncoGenex Trades Discount for Prestige in $50M Offering
By Trista Morrison
Monday, March 19, 2012
Shares of OncoGenex Pharmaceuticals Inc. fell 20.8 percent Friday after the Bothell, Wash.-based biotech priced its $50 million public offering at $12 per share.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.